DekaBank Deutsche Girozentrale Trims Stock Holdings in Moderna, Inc. $MRNA

DekaBank Deutsche Girozentrale lessened its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 0.7% in the 2nd quarter, Holdings Channel.com reports. The firm owned 220,245 shares of the company’s stock after selling 1,473 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in Moderna were worth $6,053,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of the stock. Invesco Ltd. raised its stake in shares of Moderna by 17.5% during the first quarter. Invesco Ltd. now owns 5,883,624 shares of the company’s stock worth $166,801,000 after purchasing an additional 877,162 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Moderna by 0.3% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,597,236 shares of the company’s stock worth $101,982,000 after purchasing an additional 11,270 shares during the last quarter. Northern Trust Corp raised its stake in shares of Moderna by 5.4% during the first quarter. Northern Trust Corp now owns 3,119,626 shares of the company’s stock worth $88,441,000 after purchasing an additional 160,572 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Moderna by 12.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 2,629,865 shares of the company’s stock worth $74,557,000 after purchasing an additional 285,662 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its stake in shares of Moderna by 1.8% during the first quarter. Bank of New York Mellon Corp now owns 1,918,248 shares of the company’s stock worth $54,382,000 after purchasing an additional 34,034 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on MRNA shares. Wells Fargo & Company restated an “equal weight” rating on shares of Moderna in a research note on Sunday, July 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Moderna in a research report on Wednesday, October 8th. Leerink Partners cut their price objective on Moderna from $18.00 to $15.00 and set an “underperform” rating for the company in a research report on Friday, August 22nd. JPMorgan Chase & Co. cut their price objective on Moderna from $26.00 to $25.00 and set an “underweight” rating for the company in a research report on Thursday. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research report on Monday, October 20th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, twelve have issued a Hold rating and five have issued a Sell rating to the company. According to MarketBeat, Moderna currently has a consensus rating of “Hold” and an average price target of $36.86.

Moderna Stock Up 1.9%

MRNA opened at $26.74 on Friday. The firm has a market cap of $10.44 billion, a P/E ratio of -3.55 and a beta of 2.01. Moderna, Inc. has a 52 week low of $23.15 and a 52 week high of $57.69. The business’s fifty day simple moving average is $25.94 and its 200 day simple moving average is $27.13.

Moderna (NASDAQ:MRNA) last released its earnings results on Friday, August 1st. The company reported ($2.13) earnings per share for the quarter, topping the consensus estimate of ($2.99) by $0.86. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.The firm had revenue of $142.00 million for the quarter, compared to the consensus estimate of $116.26 million. During the same period in the prior year, the business posted ($3.33) earnings per share. The firm’s revenue for the quarter was down 41.1% compared to the same quarter last year. Moderna has set its FY 2025 guidance at EPS. As a group, equities analysts expect that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.